High purity pharmaceutical-grade water-soluble
porphyrin derivatives having a general formula given by formula 1 or 2 and new methods to prepare and use such
porphyrin derivatives: Wherein B is a ring having the structure: Wherein: R1=-CH=CH2, -CH(OAlk)CH3, -CHO, -C(O)CH3, -CH2CH3, -CH(Alk)CH(COAlk)2, -CH2CH(COAlk)2, -CH(Alk)CH2COAlk, -CH(Alk)CH2CH(OH)CH3, and -CH2CH2CH(OH)CH3 R2=-CH3, -CHO, -CH(OH)Alk, -CH=CHAlk, CH2OH, and CH2OAlk; R3=-OH, -OAlk, -NH-Alk, NH-X-COO-(HG)+, -NH-Y-NR8R9, -and NH-Y-OH; R4=-OAlk, -NH-Alk, and NH-X-COO-(HG)+; R5=-OAlk, -NH-Alk, and NH-X-COO-(HG)+; R6=H and -COOAlk; R7=-O-(HG)+, -OAlk, -NH-Alk, and -NH-X-COO-(HG)+; R8=H and Alk R9=H and Alk Wherein: -NH-X-COO-=the residue of organic
amino acid; X=alkylidene, peptides, oligopeptides and -(CH2CH2O)nCH2CH2-, wherein n=1-30; Y=alkylidene and -(CH2CH2O)nCH2CH2-, wherein n=1-30; G=a hydrophilic organic amine (fex. N-methyl-D-glucamine and other amino-group containing
carbohydrate derivatives,
TRIS, amino acids, oligopeptides); and Alk=an
alkyl substituent. An embodiment of the present invention consists of a method to prepare water-soluble
porphyrin derivatives comprising